Abstract |
|
Authors | Victoria Marco-Benedí, Estíbaliz Jarauta, Sofía Pérez-Calahorra, Ana M Bea, Fernando Civeira |
Journal | Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
(Clin Investig Arterioscler)
2019 Mar - Apr
Vol. 31
Issue 2
Pg. 89-92
ISSN: 1578-1879 [Electronic] Spain |
Vernacular Title | Tratamiento de un varón con enfermedad de McArdle y muy alto riesgo cardiovascular con inhibidores de PCSK9. |
PMID | 30738610
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- PCSK9 Inhibitors
- PCSK9 protein, human
- alirocumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
(adverse effects, pharmacology, therapeutic use)
- Cardiovascular Diseases
(etiology, prevention & control)
- Cholesterol, LDL
(blood)
- Glycogen Storage Disease Type V
(etiology)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, adverse effects)
- Hyperlipidemia, Familial Combined
(drug therapy)
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy)
- PCSK9 Inhibitors
- Rhabdomyolysis
(chemically induced, complications)
- Risk Factors
- Treatment Outcome
|